Business

Boehringer Ingelheim has launched the Combivent Respimat ipratropium bromide/albuterol soft mist inhaler for the treatment of COPD in the United States. The Combivent Respimat includes enough doses for 30 days, compared to the Combivent MDI, which provides only enough medication for 25 days of treatment. The Combivent MDI, which uses a CFC propellant, will be … [Read more...] about Combivent Respimat soft mist inhaler now available in US

Cystic Fibrosis Foundation Therapeutics (CFFT) will provide up to $1.4 million to Pulmatrix to support Phase 1b trials of Pulmatrix's lead candidate, PUR118, for the treatment of CF. The collaboration between the nonprofit affiliate of the Cystic Fibrosis Foundation and Pulmatrix also includes "introductions to world-class cystic fibrosis academic researchers and … [Read more...] about Pulmatrix gets funding from Cystic Fibrosis Foundation Therapeutics for development of PUR118

Teva has filed a lawsuit in the US District Court for the District of Delaware against Perrigo and Catalent after Perrigo filed an ANDA for a generic version of Teva's ProAir HFA albuterol sulfate MDI. The suit alleges infringement of US patents 7,566,445 (Medicinal aerosols and methods of delivery thereof) and 7,105,152 (Suspension aerosol formulations). The '445 … [Read more...] about Perrigo files ANDA for albuterol MDI, Teva sues for patent infringement

The FDA has approved a generic equivalent to Meda's Astepro, an azelastine nasal spray, 0.1876MG, manufactured by Apotex. Meda filed a patent infringement suit in January 2012 after Apotex submitted its ANDA. The two companies settled after a similar suit regarding Apotex's generic version of Astelin in 2008. View the FDA approval history. … [Read more...] about FDA approves Apotex azelastine nasal spray

The United States Patent and Trademark Office has issued a method of treatment patent to Aradigm for its inhaled nicotine formulations. US Patent No. 8,256,433, for Systems and Methods for Effecting Cessation of Tobacco Use, provide exclusivity for the systems until January 7, 2024. Aradigm President and CEO Igor Gonda commented, “Tobacco smoking remains an … [Read more...] about Aradigm gets new method of treatment patent for nicotine inhaler

The Federal Court of Australia has granted an injunction against Apotex, banning it from selling generic mometasone furoate nasal sprays in the country pending the outcome of a patent infringement lawsuit by Merck Sharpe & Dohme Australia. Apotex, which claims that MSD's patent is invalid, had already begun marketing the nasal sprays and intended to begin shipping … [Read more...] about Australian court issues injunction against Apotex in Nasonex case

Elevation Pharmaceuticals, which is developing several inhalation products, has agreed to be acquired by Sunovion. Both boards have approved the deal. The agreement includes an upfront payment of $100 million and milestone payments for development of Elevation's EP-101 glycopyrrolate inhalation solution that could total as much as $90 million. EP-101 is currently … [Read more...] about Elevation to be acquired by Sunovion